Diabetes Mellitus, Type 2 Clinical Trial
— GLUCOSTRESSOfficial title:
Role of Endoplasmic Reticulum Stress in the Pathophysiology of Type 2 Diabetes
The purpose of this study is to investigate whether Endoplasmic Reticulum (ER) stress
pathway is activated in peripheral tissues (adipose tissue) in insulin resistant diabetic
patients compared to healthy subjects normoglycemic matched for age and sex an to
investigate whether ER stress pathway can be activated in response to insulin. Indeed, some
preliminar on rates studies shows that ER stress pathway is activated by insulin in liver
and adipose tissue showing that hyperinsulinemia might help trigger stress path ER.
For this, we propose a case control study of type 2 diabetic patients vs control subjects in
which markers of ER stress will be evaluated from abdominal subcutaneous adipose tissue
obtained before and after euglycemic hyperinsulinemic. We chose to consider adipose tissue
subcutaneous rather than visceral adipose tissue for obvious reasons of lesser invasiveness.
Status | Active, not recruiting |
Enrollment | 40 |
Est. completion date | November 2016 |
Est. primary completion date | November 2016 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years to 60 Years |
Eligibility |
Inclusion Criteria: - Specific criteria for diabetic patients: - Having type 2 diabetes for at least 6 months - HbA1c = 8% - Treated by lifestyle and dietary rules associated or not to a hypoglycemic therapy (metformin and / or sulfamid) and / or insulin secretors dependent glucose as inhibitors of DPP4 (dipeptidyl peptidase-4): Vildagliptin, Sitagliptin, Saxagliptin - No modification of hypoglycemic therapy and / or insulin secretors for at least 3 months Specific criteria for control subjects: - Nondiabetic subjects (fasting blood glucose <7.0 mmol / l without hypoglycemic treatment). - The control subjects should be matched to patients for age (± 5 years), sex, and BMI (± 2 kg/m2). Common criteria for patients and control subjects: - Aged 18 to 60 years - Body Mass Index between 25 and 35 kg/m2 - Accepting the constraints of the protocol and who signed the informed consent - Systolic blood pressure < 160 mmHg, diastolic blood pressure < 90 mm Hg (with or without antihypertensive treatment) - Resting heart rate between 55 and 100 beats/min. - Normal laboratory tests or not clinically significant abnormality for NFS platelets, PT, aPTT, fibrinogen ALT, AST, GGT, Serum electrolytes, urea, creatinine, Uric acid Triglycerides, total cholesterol, HDL cholesterol - HCG negative blood (for female subjects) - Affiliated to the Social Security. Exclusion Criteria: - Current infections or recent infections (<10 days) - Neoplastic disorders (with the exception of carcinoma in situ of the cervix or cutaneous epithelioma), haematological, cardiovascular, psychiatric, neurological - Poisoning smoking (>10 cigarettes per day, what ever the duration of intoxication) - Treatment with insulin or glitazones Pregnancy, Breastfeeding - Body Mass Index > 35 kg/m2 - Any drug taken for less than 8 days without the inclusion of minor analgesics (aspirin, paracetamol), anti-hypertensive medications, oral hypoglycemic (metformin and sulphonylureas) and insulin secretors dependent glucose as inhibitors of DPP4 (dipeptidyl peptidase-4) and oral contraceptives. |
Observational Model: Case Control, Time Perspective: Cross-Sectional
Country | Name | City | State |
---|---|---|---|
France | Saint-Louis Hospital | Paris |
Lead Sponsor | Collaborator |
---|---|
Assistance Publique - Hôpitaux de Paris |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Show an increase in markers of ER stress in fasting patients with type 2 diabetes | Protein expression markers of ER stress pathway BiP / GRP 78, CHOP, ATF4 EDEM and XBP-1 | 2 days | No |
Secondary | Assess whether insulin induces an increase in markers of ER stress | Insulin sensitivity | 2 days | No |
Secondary | Insulin secretion in response to glucose infusion | 2 days | No | |
Secondary | Insulin secretion in response to arginine infusion | 2 days | No | |
Secondary | Lipolysis on insulin | 2 days | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05666479 -
CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
|
||
Completed |
NCT05647083 -
The Effect of Massage on Diabetic Parameters
|
N/A | |
Active, not recruiting |
NCT05661799 -
Persistence of Physical Activity in People With Type 2 Diabetes Over Time.
|
N/A | |
Completed |
NCT03686722 -
Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin
|
Phase 1 | |
Completed |
NCT02836704 -
Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose)
|
Phase 4 | |
Completed |
NCT01819129 -
Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes
|
Phase 3 | |
Completed |
NCT04562714 -
Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy
|
N/A | |
Completed |
NCT02009488 -
Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1 | |
Completed |
NCT05896319 -
Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2
|
N/A | |
Recruiting |
NCT05598203 -
Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes
|
N/A | |
Completed |
NCT05046873 -
A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People
|
Phase 1 | |
Terminated |
NCT04090242 -
Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes
|
N/A | |
Completed |
NCT04030091 -
Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus
|
Phase 4 | |
Completed |
NCT03604224 -
A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
|
||
Completed |
NCT03620357 -
Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D)
|
N/A | |
Completed |
NCT01696266 -
An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
|
||
Completed |
NCT03620890 -
Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy
|
Phase 4 | |
Withdrawn |
NCT05473286 -
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
|
||
Not yet recruiting |
NCT05029804 -
Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes
|
N/A | |
Completed |
NCT04531631 -
Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes
|
Phase 2 |